Expanded Investment Will Allow Genentech’s East Coast Manufacturing Facility to Boost Production Output

Genentech increased its investment in a new Holly Springs, NC manufacturing facility. The company’s financial decision will more than double the initial total commitment for the company’s first East Coast manufacturing facility to approximately $2 billion.

This investment is on top of the initial commitment in May 2025, and groundbreaking in August 2025, reflecting Genentech’s continued confidence in the region’s community, workforce, and long-term growth potential, said Ashley Magargee, Genentech’s CEO, adding that the investment is expected to add an additional 100 new jobs to the NC economy, with the project supporting more than 500 manufacturing jobs and 1,500 construction jobs.

“Genentech’s increased investment in Holly Springs creates durable jobs and strengthens our life sciences sector,” notes North Carolina Governor Josh Stein. “This expansion reinforces North Carolina’s role in supporting innovation, workforce development, and long-term economic opportunity.”

Set to be operational by 2029, the expanded investment allows Genentech to build out additional production capacity and significantly increase the facility’s output, continued Magargee.

In addition to Genentech, CSL Seqirus, FUJIFILM Biotechnologies, Amgen, and others have already made investments in the Holly Springs community.